COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs

Area of Science:

• Virology
• Immunology
• Rheumatology

Background:

• COVID-19, caused by SARS-CoV-2, emerged in 2019, leading to a global pandemic with severe respiratory illness.
• SARS-CoV-2 is a betacoronavirus with structural and nonstructural proteins crucial for infectivity.
• The host immune response is vital, but excessive inflammation (cytokine storm) can cause acute respiratory distress syndrome.

Purpose of the Study:

• To review the structural features of SARS-CoV-2.
• To examine the host immune response to SARS-CoV-2 and the cytokine storm.
• To explore potential anti-inflammatory treatments used in rheumatology for severe COVID-19.

Main Methods:

• Literature review focusing on SARS-CoV-2 structure.
• Analysis of host immune responses, including innate and adaptive immunity.
• Investigation of cytokine storm pathophysiology and its link to COVID-19 severity.

Main Results:

• Preliminary studies suggest immune-modulatory treatments may help manage severe COVID-19.
• Hydroxychloroquine and cytokine antagonists (IL-6, IL-1) are being considered.
• Understanding the virus-host interaction is key to developing effective therapies.

Conclusions:

• The pathophysiology of severe COVID-19 and optimal treatments remain under investigation.
• Anti-inflammatory and immune-modulatory therapies, particularly those from rheumatology, show promise.
• Further research is needed to establish the efficacy of these treatments for COVID-19.